H. Lundbeck A/S has planned the following dates in 2010 for the
financial statements, the Annual General Meeting and payment of
annual dividend.
4 March 2010 Annual
report 2009
20 April 2010 Annual
General Meeting
26 April 2010 Payment
of annual dividend
6 May 2010 Interim
report for the first quarter of 2010
13 August 2010 Interim
report for the second quarter of 2010
3 November 2010 Interim report
for the third quarter of 2010
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Mads Kronborg
Director, IR & Communication Media Relations Manager
+45 36 43 30 79 +45 36 43 28 51
Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26
Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international
pharmaceutical company highly committed to improve the quality of
life for people suffering from central nervous system (CNS)
disorders. For this purpose Lundbeck is engaged in the research and
development, production, marketing and sale of pharmaceuticals across
the world, targeted at disorders like depression and anxiety,
schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's
diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark,
and employs today over 5,500 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders.
In 2008, the company's revenue was DKK 11.3 billion (approximately
EUR 1.5 billion or USD 2.2 billion). For more information, please
visit www.lundbeck.com.
